Adaptive Servo-Ventilation In Acute Heart Failure Patients Protecting the Heart and Kidneys

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary hypothesis of this study is: the use of minute ventilation-adaptive servo-ventilation (MV-ASV) during hospitalization will mitigate deterioration in renal function and prevent kidney injury in patients admitted with acute heart failure (AHF) compared to those receiving usual care. We will validate and extend our pilot study by taking a deeper dive into the effects of ASV on diuretic dose, urine output and new and exciting biomarkers of renal function and kidney injury. If our hypothesis proves correct, it strongly suggests that ASV lessens injury to the kidney and could lead to a new paradigm for the treatment of AHF. When use of high dose of diuretics are anticipated or in whom chronic kidney disease (CKD) or acute kidney injury (AKI) is present on arrival to the Emergency Department, use of MV-ASV might decrease the amount of diuretics needed, allow for continued use of ACE inhibitors, and ultimately mitigate rises in creatinine and decreases in effective glomerular filtration. Since kidney injury is a major factor in those patients with early 30-day readmission following discharge, this therapy could become quite popular.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

NCT01953874

Acute Decompensated Heart Failure Sleep Disordered Breathing

TERMINATED NA

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

NCT00733343

Heart Failure Sleep Disordered Breathing

COMPLETED NA

Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure

NCT01128816

Sleep Apnea Heart Failure

TERMINATED NA

Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure

NCT00751972

Chronic Heart Failure

COMPLETED NA

Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure

NCT02254382

Diastolic Heart Failure

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVE(S): The main goal of this study is to evaluate the utility of a Minute Ventilation Adaptive Servo-ventilation (MV-ASV) device in mitigating deterioration in renal function and prevent kidney injury in patients admitted with acute heart failure compared to those receiving usual care. We will be assessing the effects of MV-ASV on diuretic dose, urine output and new and exciting biomarkers of renal function and kidney injury. If our hypothesis proves correct, it strongly suggests that ASV lessens hypoxia to the kidney and could lead to a new paradigm for the treatment of AHF. When use of high dose of diuretics are anticipated or in whom CKD or AKI is present on arrival to the Emergency Department, use of MV-ASV might decrease the amount of diuretics needed, allow for continued use of ACE inhibitors, and ultimately mitigate rises in creatinine and decreases in effective glomerular filtration. Since kidney injury is a major factor in those patients with early 30-day readmission following discharge, this therapy could become quite popular.

RESEARCH DESIGN: This is an interventional, principal investigator-initiated project with patient enrollment, cohort development and data analysis. We will recruit 66 patients with acute heart failure and evidence of volume overload and elevated BNP, since we anticipate a 10% dropout. Half will be pre-selected to have CKD with eGFR \< 60 ml/min/1.73 m2. Randomization will be attempted within first six hours of hospital presentation. The participants will be randomized one of the following two groups: 1) those receiving only standard therapy or 2) those receiving standard therapy and adaptive servo-ventilation (ASV) therapy.

METHODOLOGY:

Methods:

1. Consenting of patient: every attempt will be made to consent within six hours of evaluation, as we feel there is a good window for ASV here. Maximum time to consent is 24 hours.
2. Sleep and breathing assessment: Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Pulmonary Sleep Lab Questionnaire, Sleep Diary, Likert Scale
3. Blood Sample Collections:
4. Two 10cc (20cc total) blood samples in standard collection tubes will be obtained via venipuncture or a peripheral IV line from each enrolled patient at the time of enrollment.
5. One sample will be collected in a lithium heparin tube and the other sample will be collected in an EDTA tube. Initial blood samples will be collected after the initiation of standard medical therapy and stabilization for acute heart failure.
6. The blood samples will be analyzed for cardiac biomarkers such as BNP, high sensitivity troponins (hsTnI), endothelin-1 (ET-1), kidney injury molecule-1 (KIM-1) by Singulex, and adrenomedullin (hADM) by Sphingotec.

Remaining blood samples will be banked for future biomarker analysis. All samples will be held at the VASDHS in a clinical laboratory storage facility indefinitely for future analysis of biomarkers such as those of inflammation, fibrosis and cardiorenal syndrome. NO GENETIC TESTING will be done on the samples.
7. As obligated, we will report any incidental findings of FDA approved biomarkers performed, as a part of further analysis of banked specimens, to the patient through their treating physicians.
8. All specimens will be frozen at -80 degrees Celsius for storage.
9. Specimens with evidence of hemolysis will not be analyzed.
10. MV-ASV Treatment and Respiration Monitoring:

* Adaptive Servo-Ventilation (ASV) therapy will be placed on the patient by the respiratory therapy team as soon as the patient is enrolled in the study. The ASV device will be on ASV Auto mode, which has an automatic expiratory positive airway pressure (EPAP) adjustment based on the patient's breathing. The ASV Auto default EPAP range is 4-15cmH2O with a pressure support range of 3-15cmH2O. The backup rate of the ASV is adaptive based on the patient's respiratory rate. However, if the automatic ventilation setting is not suitable to maintain target ventilation, then a setting of 15 breaths per minute will be used.
* We will ask the patients to use the ASV therapy during all hours of sleeping during their stay in the hospital and during times when they are awake, if they feel comfortable using it.
* The patient will be closely monitored during the first few hours to make sure the patients are comfortable, have the right settings and are without mask leaks. The monitoring team will consist of members from Cardiology, Pulmonary Critical Care and Respiratory Therapy.
11. Repeat following assessments in the hospital each day for up to five days

* Two tubes of 10cc each (20 cc total)
* Likert dyspnea assessment
* Sleep diary entry once each day for up to 5 days
* Urine outputs
* Daily weights
* Dose of diuretics
12. Additional hospital data to be recorded:

* Presence of arrhythmias
* Need for inotropes
* Need for intubation
* Number of ICU days
* Total number of hospital days
* Need for renal consult
* Electrolytes
* BNP
* Troponins
13. Once the subject is discharged from the hospital, the following will happen:

* They will be seen at 30 days for following:
* Evaluation for events
* Sleepiness scales: Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Pulmonary Sleep Lab Questionnaire, Sleep Diary, Likert Scale
* Two tubes of blood (10cc each) will be drawn, as described above to assess renal function and AKI
* They will not be reimbursed for this visit
14. Power analysis • The comparison of groups of size 30 and 30 has a power of 0.815 to detect an effect equal to a group difference of (0.75) standard deviations. This would apply to all variables in univariate tests at significance level of 0.05 with appropriate corrections for multiple comparisons.

CLINICAL RELATIONSHIPS: The potential benefit of this study includes the validation of the use of an ASV device in the treatment of heart failure. ASV treatment might decrease the amount of diuretics needed, allow for continued use of ACE inhibitors, and ultimately mitigate rises in creatinine and decreases in effective glomerular filtration. ASV treatment may lessen hypoxia to the kidney and could lead to a new paradigm for the treatment of AHF.

IMPACT/SIGNIFICANCE: Heart failure is a major cause of both death and healthcare spending in the United States. ASV is a cost effective, non-invasive treatment that can improve symptoms and cardiac outcomes in patients with heart failure. Validation of an MV-ASV device as an effective treatment could help improve prognosis and quality of life in patients with this often terminal condition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Sleep Apnea, Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Minute Ventilation Adaptive Servo-Ventilation plus SOC

Patients in this arm will be instructed to use the adaptive servo-ventilation (ASV) device for up to five days of inpatient stay while in the hospital. Patients are encouraged to use the device during any and all hours of sleep, and as needed during waking hours. Apart from this treatment, no other interventions will be administered, and the patient's standard of care will not otherwise be altered for the purposes of the study.Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.

Group Type EXPERIMENTAL

Adaptive Servo-Ventilation

Intervention Type DEVICE

A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.

Standard of Care (SOC)

Patients in this arm will not have their standard of care as dictated by their provider altered in any way. Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adaptive Servo-Ventilation

A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18 years and older.
2. Admitted with a clinical diagnosis of acute heart failure.
3. Evidence of congestion (rales, JVP, CXR, edema).
4. BNP \>300pg/mL
5. If BMI \>35 kg/m2, then BNP \>100 pg/ml.
6. Consent within 24 hours of admission, but every attempt will be made to consent within six hours.
7. Patients with known sleep disordered breathing (SDB) can be included.
8. One-half of patients in each group will have chronic kidney disease (CKD) with GFR less than 60.

Exclusion Criteria

1. Age \< 18 years.
2. Unable to provide informed consent within 24 hours of admission.
3. Current participation in a pharmaceutical or treatment-related clinical study.
4. Intubated.
5. Hypercarbic (ie. Acute Respiratory Acidosis) from reasons other than acute heart failure.
6. Cardiogenic shock.
7. Clinical diagnosis of COPD exacerbation as the primary reason for hospital admission.
8. History of non-compliance to medications and treatment.
9. Pregnant women.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No